Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

Small-molecule inhibitors of tyrosine kinases (TKIs) are the mainstay of treatment for many
malignancies and represent novel treatment options for other diseases such as idiopathic …

Preclinical evaluation of novel cancer agents requires models that accurately reflect the
biology and molecular characteristics of human tumors. Molecular profiles of eight …

Tyrosine kinase inhibitors are a class of chemotherapeutic drugs that target specific protein
kinases. These tyrosine kinase inhibitors constitute a relatively new class of drugs which …

Epidermal growth factor receptor (EGFR) is a transmembrane protein commonly targeted by
tyrosine kinase inhibitors (TKIs) as a front-line therapy for patients with many cancers …

Background. We aimed to investigate the distributive characteristics of SLC22A1 rs594709
and SLC47A1 rs2289669 polymorphisms and their influence on metformin efficacy in …

Genome-wide association studies have identified a signal at the SLC22A1 locus for serum
acylcarnitines, intermediate metabolites of mitochondrial oxidation whose plasma levels …

Changes in the uptake of many drugs by the target cells may dramatically affect the
pharmacological response. Thus, downregulation of SLC22A1, which encodes the organic …

Imatinib is a highly effective therapy for chronic phase-chronic myeloid leukaemia (CP-CML)
patients; however, responses to frontline imatinib are variable. The human organic cation …

Aim: Large interindividual variability in morphine pharmacokinetics (PK) could contribute to
variability in morphine analgesia and adverse events. Respiratory depression (RD) and …